# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Morgan Stanley analyst Michael Ulz initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a Overweight rating and anno...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $90 p...
Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of nove...
Truist Securities analyst Joon Lee maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $120 price target.